ASTHMA CONTROL WITH ICS-FORMOTEROL RELIEVER VS MAINTENANCE ICS AND SABA RELIEVER THERAPY: A POST HOC ANALYSIS OF TWO RANDOMISED CONTROLLED TRIALS

Lee Hatter, Claire Houghton, Pepa Bruce, Mark Holliday, Allie Eathorne, Ian D Pavord, Helen K Reddel, Robert J Hancox, Irene Braithwaite, Karen Oldfield, Alberto Papi, Mark Weatherall, Richard Beasley

ONLINE SUPPLEMENT
Figure S1: Alluvial plot displaying the frequency (n) of participants in each ACQ-5 group category: ‘well-controlled’ (≤0.75), ‘partly-controlled’ (>0.75 to <1.5), and ‘inadequately-controlled’ (≥1.5) asthma by visit, and the changes in flow from Visit 1 (Week 0) to Visit 7 (Week 52), for A) Budesonide-formoterol as needed, and B) Budesonide maintenance, for Novel START. The colour of the flow between visit nodes represents the ACQ-5 group category at Visit 1. Missing data are excluded.

A | Budesonide-formoterol as needed
Figure S2: Alluvial plot displaying the frequency (n) of participants in each ACQ-5 group category: ‘well-controlled’ (≤0.75), ‘partly-controlled’ (>0.75 to <1.5), and ‘inadequately-controlled’ (≥1.5) asthma by visit, and the changes in flow from Visit 1 (Week 0) to Visit 6 (Week 52), for A) Budesonide-formoterol as needed, and B) Budesonide maintenance, for PRACTICAL. The colour of the flow between visit nodes represents the ACQ-5 group category at Visit 1. Missing data are excluded.

A | Budesonide-formoterol as needed